Vorasidenib Tablets 10 mg, 40 mg Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 10 mg, 40 mg
Reference Brands: Voranigo
Category: Oncology Cancer Care
Vorasidenib (Voranigo, Servier) is a brain-penetrant IDH1 and IDH2 inhibitor for grade 2 IDH-mutant astrocytoma and oligodendroglioma, approved by the US FDA in 2024 and in the EU in 2025. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.
Manufacture or export Vorasidenib Tablets? List it or send an offer →
Product Description:
Vorasidenib blocks mutant forms of the enzymes IDH1 and IDH2. In IDH-mutant gliomas these enzymes produce 2-hydroxyglutarate, a metabolite that disturbs how genes are switched on and drives tumour growth. Vorasidenib crosses into the brain and lowers 2-hydroxyglutarate in the tumour. It is the first targeted therapy for these gliomas.
The US FDA approved vorasidenib as Voranigo in August 2024, and the European Commission followed in September 2025. It is used for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, in patients aged 12 and over, after surgery. In its main trial it delayed progression and the need for radiotherapy and chemotherapy. It is taken once a day, usually 40 mg (20 mg for patients under 40 kg), and liver tests are monitored.
Sourcing and licensing notes. Vorasidenib is patented and made only by Servier; there is no generic. We handle enquiries for authorised supply of Voranigo where import is allowed and connect developers and licensees interested in the molecule ahead of patent expiry.
How Vorasidenib Tablets is supplied today, and licensing ahead of patent expiry
Where vorasidenib is approved
Checked 3 Oct 2026| Market | Status | Brand · regulator · date |
|---|---|---|
| United States | Approved | Voranigo · FDA · Aug 2024 |
| European Union | Approved | Voranigo · European Commission · Sep 2025 |
| Generic / biosimilar | None | None approved as of the check date |
Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →
Frequently Asked Questions
Grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation, after surgery, in patients aged 12 and over.
Voranigo, from Servier. Approved in the US in 2024 and in the EU in 2025.
Yes. It was designed to cross the blood-brain barrier, which is why it works in glioma.
No. It is patented. We handle authorised-supply enquiries and connect developers and licensees preparing for patent expiry.
Related Products
Sunvozertinib Tablets
Strength:
150 mg, 200 mg
Form: Tablets
Reference Brands: Zegfrovy
View Details
Carboplatin
Strength:
50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL
Form: Injection
Reference Brands: Paraplatin (US)
View Details
Cisplatin
Strength:
10 mg/10 mL, 50 mg/50 mL, 100 mg/100 mL (1 mg/mL)
Form: Injection
Reference Brands: Platinol (US)
View Details
Cyclophosphamide
Strength:
Tablets 25 mg, 50 mg, 100 mg; injection 200 mg/2 mL, 500 mg/5 mL
Form: Tablets, injection
Reference Brands: Cytoxan (US), Endoxan (EU)
View Details
Enzalutamide
Strength:
Capsules 40 mg; tablets 40 mg, 80 mg
Form: Capsules, tablets
Reference Brands: Xtandi (US/EU)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit
